KRAS and neoplasm: For instance, the potential neoantigen based on BRAF V600E mutation and HLA-A03:01 exists in 117 tumor samples, and corresponding neoantigens based on several mutations of KRAS and PIK3CA are also shared in more than 40 tumor samples (Table 1).